Drw Securities, LLC Vertex Pharmaceuticals Inc Transaction History

Drw Securities, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$392.81 - $485.53 $481,192 - $594,774	-1,225 Reduced 62.28%	742 $347,000
Q1 2024 May 14, 2024	BUY	$407.69 - $446.08 $801,926 - $877,439	1,967 New	1,967 $822,000
Q3 2023 Nov 13, 2023	SELL	$338.18 - $362.46 $316,536 - $339,262	-936 Reduced 60.5%	611 $212,000
Q2 2023 Aug 14, 2023	BUY	$314.42 - $351.91 $486,407 - $544,404	1,547 New	1,547 $544,000
Q3 2021 Nov 12, 2021	SELL	$181.39 - $202.99 $196,808 - $220,244	-1,085 Closed	0 $0
Q2 2021 Aug 12, 2021	BUY	$187.49 - $221.1 $203,426 - $239,893	1,085 New	1,085 $219,000
Q2 2020 Aug 14, 2020	SELL	$225.48 - $295.8 $306,201 - $401,696	-1,358 Closed	0 $0
Q1 2020 May 13, 2020	BUY	$199.77 - $247.81 $271,287 - $336,525	1,358 New	1,358 $323,000
Q1 2018 May 14, 2018	SELL	$151.6 - $177.13 $538,483 - $629,165	-3,552 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$137.28 - $155.55 $487,618 - $552,513	3,552	3,552 $532,000

1,724

222M

1.58M

1.36M

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $119B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

Get notified when there are updates to the investment portfolio of Drw Securities, LLC, based on Form 13F filings with the SEC.

Stay updated on Drw Securities, LLC with notifications on news.